Razi Cov Pars

Razi Cov Pars
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular, Intranasal
Legal status
Legal status

Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.[1][2][3]

It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.[4][5] It received emergency use authorization in Iran on 31 October 2021.[6][7]

Medical uses

It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).[3]

Pharmacology

Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.[2]

Manufacturing

It's planned to produce one million doses of the vaccine each month as of September 2021.[4]

As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.[8]

History

Clinical trials

Clinical trials of Razi Cov Pars
Phase Registration number Start Number of participants Age of participants Ref
Total Vaccine Placebo
I IRCT20201214049709N1 21 January 2021 133 30 (5 µg/200µL)

30 (10 µg/200µL)

30 (20 µg/200µL)

 30 (placebo)

13 (sentinel)

 18-50 years [2]
II IRCT20201214049709N2 13 April 2021 500 18-70 years [3]
III IRCT20201214049709N3 29 August 2021 41,128 20,564 0 (placebo)

20,564 (Sinopharm BIBP vaccine)

 18+ years [5]

Authorizations

Raz Cov Pars received emergency use authorization in Iran on 31 October 2021.[6][7]

See also

References

  1. 1 2 Mehdi, Syed Zafar (7 February 2021). "Iran unveils second homegrown COVID-19 vaccine". Anadolu Agency. Retrieved 22 April 2021.
  2. 1 2 3 "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.{{cite web}}: CS1 maint: url-status (link)
  3. 1 2 3 "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.{{cite web}}: CS1 maint: url-status (link)
  4. 1 2 "COVID-19 vaccine Razi Cov Pars starts third clinical trial phase". Tehran Times. 27 August 2021. Retrieved 30 August 2021.
  5. 1 2 "IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial". en.irct.ir. Retrieved 30 August 2021.
  6. 1 2 "مجوز مصرف اضطراری داوطلبانه واکسن کووپارس صبح امروز صادر شد". ایسنا (in Persian). 31 October 2021. Retrieved 27 November 2021.
  7. 1 2 "Two homegrown vaccines receive emergency use license". Tehran Times. 1 November 2021. Retrieved 27 November 2021.
  8. ↑ "۵ میلیون دز واکسن رازی به وزارت بهداشت تحویل داده شد". ایسنا (in Persian). 25 November 2021. Retrieved 27 November 2021.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.